Chickenpox vaccines. A favourable risk-benefit balance in some situations

Prescrire International

Volumn 14, Issue 77, 2005, Pages 85-91

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHICKENPOX VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

ACUTE LYMPHOCYTIC LEUKEMIA; AGE; ARTICLE; BACTERIAL INFECTION; CEREBELLAR ATAXIA; CHICKENPOX; CLINICAL TRIAL; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FEBRILE CONVULSION; FEVER; FOLLOW UP; FRANCE; GASTROINTESTINAL DISEASE; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; INJECTION SITE REACTION; KIDNEY TRANSPLANTATION; MENINGITIS; NEUROLOGIC DISEASE; PNEUMONIA; PREGNANCY; PREGNANCY COMPLICATION; RASH; REYE SYNDROME; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN INFECTION; SOLID TUMOR; VACCINATION; VARICELLA ZOSTER VIRUS; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; FEMALE; IMMUNOLOGY; MASS IMMUNIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HERPES ZOSTER; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; MASS IMMUNIZATION; PREGNANCY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 20344381540     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Prescrire Rédaction "Reconnaître les varicelles graves" Rev Prescrire 2003; 23 (236): 114-120.
2. Boëlle PY and Hanslik T "Varicella in non-immune persons: incidence, hospitalization and mortality rates" Epidemiol Infect 2002; 129: 599-606.
3. Mallet E et al. "Evaluation des complications de la varicelle à partir d'une enquête hospitalière rétrospective menée dans un service de pédiatrie pendant 16 ans en France" Arch Péd 2004; 11: 1145-1151.
4. Prescrire Rédaction "Vaccin varicelle - Vaccin varicelle Mérieuxo" Rev Prescrire 1995; 15 (150): 260-262.
5. Arvin AM "Varilrix GlaxoSmithKline" Curr Opin Invest Drugs 2002; 3 (7): 996-999.
6. Meurice F et al. "Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children" J Infect Dis 1996; 174 (suppl. 3): 324-329.
7. Watson B and Rothstein E "Varicella vaccine: progress 4 years after licensure" Pediatr Annals 1998; 28 (8): 516-529.
8. "Varivax III - Product monograph - Canada" March 2003: 10 pages.
9. US Food and Drug Administration "Varivaxo - Summary for basis of approval" January 1995: 22 pages.
10. Comité consultatif national de l'immunisation (CCNI) "Mise à jour sur la varicelle" RMTC 2004; 30: 1-28.
11. La Russa P et al. "Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada" J Infect Dis 1996; 174 (suppl. 3): 320-323.
12. Gershon AA et al. "Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children" J Infect Dis 1990; 161: 661-666.
13. Slordahl SH et al. "Vaccination of children with malignant disease against varicella" Postgrad Med J 1985; 61 (suppl. 4): 85-92.
14. Ninane J et al. "Live varicella vaccine in severely immunodepressed children" Postgrad Med J 1985; 61 (suppl. 4): 97-102.
15. Haas RJ et al. "Active immunization against varicella of children with acute leukaemia or other malignancies on maintenance chemotherapy" Postgrad Med J 1985; 61 (suppl. 4): 69-72.
16. Vialatte J et al. "Essais d'un vaccin contre la varicelle chez 100 enfants à haut risque" Dev Biol Stand 1982; 52: 385-390.
17. Hardy I et al. "The incidence of zoster after immunization with live attenuated varicella vaccine" N Engl J Med 1991; 325: 1545-1550.
18. Gershon AA et al. "The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox" J Infect Dis 1996; 173 (1): 450-453.
19. Austgulen R "Immunization of children with malignant disease with the Oka-strain varicella vaccine" Postgrad Med J 1985; 61 (suppl. 4): 93-95.
20. Heath RB and Malpas JS "Experience with the live Oka-strain varicella vaccine in children with solid tumours" Postgrad Med J 1985; 61 (suppl. 4): 107-111.
21. Heller L et al. "Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden" Postgrad Med J 1985; 61 (suppl. 4): 79-83.
22. Heath RB et al. "Efficacy of varicella vaccine in patients with solid tumours" Arch Dis Child 1987; 62: 569-572.
23. Zamora I et al. "Attenuated varicella virus vaccine in children with renal transplants" Pediatr Nephrol 1994; 8: 190-192.
24. Broyer M and Tete MJ "Varicella and zoster in children after kidney transplantation: long-term results of vaccination" Pediatrics 1997; 99 (1): 35-39.
25. Gagnadoux MF et al. "Prévention de la varicelle chez les transplantés rénaux" J Pediatr Puericulture 1998; 11 (4): 226-229.
26. Levin MJ et al. "Immunization of HIV-infected children with varicella vaccine" J Pediatr 2001; 139: 305-310.
27. SmithKline Beecham Biologicals "Varilrixo - Tableaux résumés" Undated: 91 pages.
28. "Varilrixo - Summary of Product Characteristics - United Kingdom" 2 August 2002: 10 pages.
29. Ngai A et al. "Safety and immunogenicity of one versus two injections of Oka/Merck varicella vaccine in healthy children" Pediatr Inf Dis J 1996; 15 (1): 49-54.
30. Weibel RE et al. "Live attenuated varicella virus vaccine" N Engl J Med 1984: 310: 1409-1415.
31. White CJ et al. "Varicella vaccine (Varivaxo) in healthy children and adolescents: results from clinical trials, 1987 to 1989" Pediatrics 1991; 87 (5): 604-610.
32. Kuter BJ et al. "Safety, tolerability and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivaxo) in healthy adolescents and adults" Vaccine 1995; 13 (11): 967-972.
33. Lau YL et al. "A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and Varilrixo in healthy children" Vaccine 2002; 20: 2942-2949.
34. Varis T and Vesikari T "Efficacy of high-titer live attenuated varicella vaccine in healthy young children" J Infect Dis 1996; 174 (suppl. 3): 330-334.
35. Schieifele DW et al. "Three-year follow-up of protection rates in children given varicella vaccine" Can J Infect Dis 2002; 13 (6): 382-386.
36. Agence française de sécurité sanitaire des produits de santé "Varivax - résumé des caractéristiques du produit" 20 July 2004: 11 pages.
37. Kuter BJ et al. "Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies" Vaccine 1991; 9: 643-647.
38. Kuter B et al. "Ten year follow-up of healthy children who received one or two injections of varicella vaccine" Pediatr Infect Dis J 2004; 23 (2): 132-137.
39. White CJ "Varicella zoster virus vaccine" Clin Infect Dis 1997; 24: 753-763.
40. Centers for Disease Control and Prevention "Varicella vaccine". Website http://www.cdc.gov/nip/vaccine/varicella/faqs/clinic-vaccine.htm searched on 12 January 2004: 7 pages.
41. Gentile A et al. "Efectividad de la vacuna anti-varicela-zoster como profilaxis post-exposicion" Arch Argent Pediatr 2002; 100 (1): 25-30.
42. Salzman MB and Garcia C "Postexposure varicella vaccination in siblings of children with active varicella" Pediatr Infect Dis 1998; 17 (3); 256-257.
43. Watson B et al. "Postexposure effectiveness of varicella vaccine" Pediatrics 2000; 105 (1): 84-88.
44. Wise RP et al. "Postlicensure safety surveillance for varicella vaccine" JAMA 2000; 284 (10): 1271-1279 + Correction (24): 3129.
45. Sharrar RG et al. "The postmarketing safety profile of varicella vaccine" Vaccine 2001; 19: 916-923.
46. "Varilrixo" - Product monograph - Canada" 12 September 2002: 12 pages.
47. Levin MJ et al. "Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-Zoster virus, in an immunosuppressed child" J Infect Dis 2003; 188: 954-959.
48. Levy O et al. "Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells" J Infect Dis 2003; 188: 948-953.
49. Kramer JM et al. "Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome - defining illness in a previously undiagnosed child" Pediatrics 2001; 109: 39.
50. Ghaffar F et al. "Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency" Pediatr Infect Dis 2000; 19 (8): 764-766.
51. Prescrire Rédaction "Varicelle et grossesse = danger" Rev Prescrire 1994; 14 (142): 429.
52. Bruel H et al. "À propos de deux cas de varicelle congénitale: plaidoyer pour la vaccination des femmes en âge de procréer" Arch Péd 2004; 11: 216-218.
53. Shields KE et al. "Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry" Obstet Gynecol 2001; 98 (1): 14-19.
54. Ministère de la santé et de la protection sociale - Direction générale de la santé "Avis du conseil supérieur d'hygiène publique de France, section maladies transmissibles, relatif à la vaccination contre la varicelle" 19 March 2004: 6 pages.
55. Gershon AA et al. "Immunization of healthy adults with live attenuated varicella vaccine" J Infect Dis 1988; 158 (1): 132-137.
56. SmithKline Beecham "Study report 208133/100 (OKA-H-024) Annex-3" 20 November 1998: 4 pages.